Institutional investors purchased a net $196.3 thousand shares of CLLS during the quarter ended March 2019. This may signal that the smart money is gaining interest in this company as the 22.53% of shares outstanding that institutional investors hold is actually below the Biotechnology industry average.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
BAILLIE GIFFORD & CO. Sold 188.9 Thousand shares of Cellectis SA